Clinical trial • Phase III • Oncology
Clinical trial in Advanced cancer
Phase III trial for Advanced cancer. None/Not specified-controlled. 24 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced cancer
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 05-12-2025
- First CTIS Authorization Date
- 14-04-2026
Trial design
None/Not specified-controlled Phase III trial across 9 sites in France, Italy, Spain.
- Comparator
- None/Not specified
- Target Sample Size
- 24
Recruitment
- Planned Sample Size
- 24
- Recruitment Window Months
- 30
Geography
- Total Number Of Sites
- 9
- Total Number Of Participants
- 24
France
- Earliest CTIS Part Ii Submission Date
- 08-01-2026
- Latest Decision Or Authorization Date
- 14-04-2026
- Processing Time Days
- 96
- Number Of Sites
- 2
- Number Of Participants
- 5
Sites
- Site Name
- Centre Hospitalier Universitaire De Nantes
- Department Name
- Oncologie Médicale
- Contact Person Name
- Mario Campone
- Contact Person Email
- mario.campone@ico.unicancer.fr
- Site Name
- Centre Hospitalier Universitaire De Bordeaux
- Department Name
- Oncologie Médicale
- Contact Person Name
- Amaury Daste
- Contact Person Email
- amaury.daste@chu-bordeaux.fr
Italy
- Earliest CTIS Part Ii Submission Date
- 23-02-2026
- Latest Decision Or Authorization Date
- 15-04-2026
- Processing Time Days
- 51
- Number Of Sites
- 2
- Number Of Participants
- 4
Sites
- Site Name
- Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
- Department Name
- Medical Oncology
- Contact Person Name
- Vanesa Gregorc
- Contact Person Email
- vanesa.gregorc@ircc.it
- Site Name
- Istituto Europeo Di Oncologia S.r.l.
- Department Name
- Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative
- Contact Person Name
- Giuseppe Curigliano
- Contact Person Email
- giuseppe.curigliano@ieo.it
Spain
- Earliest CTIS Part Ii Submission Date
- 23-03-2026
- Latest Decision Or Authorization Date
- 17-04-2026
- Processing Time Days
- 25
- Number Of Sites
- 5
- Number Of Participants
- 15
Sites
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Oncology
- Contact Person Name
- Emiliano Calvo Aller
- Contact Person Email
- emiliano.calvo@startmadrid.com
- Site Name
- Hospital Quironsalud Barcelona
- Department Name
- Oncology
- Contact Person Name
- Fabricio Racca Bussano
- Contact Person Email
- fracca@nextoncology.eu
- Site Name
- Hospital Universitario Quironsalud Madrid
- Department Name
- Oncology
- Contact Person Name
- Valentina Boni
- Contact Person Email
- vboni@nextoncology.eu
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Oncology
- Contact Person Name
- Manuel Pedregal Trujillo
- Contact Person Email
- manuel.pedregal@startmadrid.com
- Site Name
- Hospital Hm Nou Delfos
- Department Name
- Oncology
- Contact Person Name
- Tatiana Hernandez Guerrero
- Contact Person Email
- tatiana.hernandez@start-barcelona.com
Sponsor
Primary sponsor
- Full Name
- Novartis Pharma AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Related trials
Other published trials that may interest you.